A study, published in Cancer Cell, shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United ...

A common gastrointestinal cancer drug that crosses the blood-brain barrier showed promise in patients with aggressive ...

Mar. 13, 2025 — A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States ...

A study is recruiting patients with systemic mastocytosis (SM) with an associated hematologic neoplasm (SM-AHN) to evaluate the safety and tolerability of combination therapy with avapritinib and ...

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceuticals.

TLX101 treatment in recurrent high-grade glioma showed a median overall survival of 12.4 months, with no serious side effects reported. The study supports the potential for higher therapeutic doses of ...

Although it has been shown that LAT1/4F2hc is highly expressed in a variety of human tumors including gliomas, and LAT1 over-expression is associated with glioma grade and poor prognosis of glioma ...

有希望的早期临床数据 最后，在小鼠模型中进行了额外的测试后，研究人员通过一项富有同情心的使用计划，用avapritinib治疗了8名患有高度胶质瘤的儿童和年轻成人患者。大多数患者有dmg， 8人中有7人有PDGFRA改变。所有患者之前都接受过手术活检或切除和放疗 ...